Literature DB >> 10994833

Naproxen-associated linear IgA bullous dermatosis: case report and review.

M B Bouldin1, H E Clowers-Webb, J L Davis, M T McEvoy, M D Davis.   

Abstract

Linear IgA bullous dermatosis (LABD) is an acquired autoimmune subepidermal blistering disorder in which linear deposits of IgA are found along the basement membrane. Idiopathic, systemic disorder-related, and drug-induced forms of LABD have been described. Drug-induced LABD occurs in association with drug administration and resolves when the offending agent is discontinued. Other forms of LABD assume a more chronic course. The nonsteroidal anti-inflammatory drugs piroxicam and diclofenac have been previously reported to induce LABD. To our knowledge, this article describes the first documented case of LABD associated with naproxen administration, which resolved after discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994833     DOI: 10.4065/75.9.967

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

Authors:  Bethsabée Garel; Saskia Ingen-Housz-Oro; Daniele Afriat; Catherine Prost-Squarcioni; Florence Tétart; Benoit Bensaid; Corina Bara Passot; Marie Beylot-Barry; Vincent Descamps; Sophie Duvert-Lehembre; Sabine Grootenboer-Mignot; Géraldine Jeudy; Angèle Soria; Marie Blanche Valnet-Rabier; Annick Barbaud; Frédéric Caux; Bénédicte Lebrun-Vignes
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

2.  Linear IgA bullous dermatosis: an association with ulcerative colitis versus renal cell carcinoma.

Authors:  A Scott Keller; Molly B Bouldin; Lisa A Drage; Stephen C Hauser; Mark D P Davis
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

3.  Topical imiquimod-induced linear IgA bullous dermatosis.

Authors:  Giulia Tadiotto Cicogna; Martina Ferranti; Daniele Vaccari; Mauro Alaibac
Journal:  BMJ Case Rep       Date:  2019-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.